Immune Design Corp. (NASDAQ:IMDZ) Director Lewis W. Coleman acquired 50,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was acquired at an average price of $4.50 per share, for a total transaction of $225,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Immune Design Corp. (NASDAQ:IMDZ) traded up $0.35 during midday trading on Monday, reaching $4.50. The company’s stock had a trading volume of 465,276 shares, compared to its average volume of 1,561,564. Immune Design Corp. has a 52 week low of $3.78 and a 52 week high of $13.05.
Immune Design Corp. (NASDAQ:IMDZ) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%. equities analysts predict that Immune Design Corp. will post -1.87 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Immune Design Corp. (IMDZ) Director Lewis W. Coleman Acquires 50,000 Shares” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/06/immune-design-corp-imdz-director-lewis-w-coleman-acquires-50000-shares.html.
Several brokerages have recently issued reports on IMDZ. Royal Bank Of Canada began coverage on Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price on the stock. ValuEngine cut Immune Design Corp. from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Wells Fargo & Company cut Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. Finally, Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Immune Design Corp. presently has a consensus rating of “Buy” and an average price target of $13.19.
Several institutional investors and hedge funds have recently added to or reduced their stakes in IMDZ. FMR LLC grew its stake in shares of Immune Design Corp. by 0.4% during the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 1,699 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in shares of Immune Design Corp. by 18.9% during the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 7,236 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Immune Design Corp. by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 70,351 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Immune Design Corp. by 123.3% during the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares during the last quarter. Finally, Personal Capital Advisors Corp bought a new position in shares of Immune Design Corp. during the second quarter valued at approximately $356,000. 51.76% of the stock is currently owned by hedge funds and other institutional investors.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.